Pfizer’s chief scientific officer and president of R&D, Mikael Dolsten, has said he will step down from the role in the coming months, kicking off the search for a successor. Dolsten’s ...

Pfizer (NYSE:PFE) announced Tuesday that its Chief Scientific Officer and President of Research & Development (R&D), Mikael ...

Five years ago — before the pandemic — Pfizer’s head of research and development, Mikael Dolsten, told STAT he kept a chess set in his office that he got as a gift from a former CEO of the ...

US pharmaceutical giant Pfizer on Tuesday said its chief scientific officer Mikael Dolsten, a key figure behind the ...

Pfizer faced a setback with its combo Covid-flu shot, which could allow Moderna and others to gain ground. Meanwhile, Epic’s ...

Pfizer on Tuesday said Mikael Dolsten, chief scientific officer and president, Pfizer Research & Development, is leaving after more than 15 years with the drugmaker. Pfizer said it is launching ...

Pfizer’s top scientist Mikael Dolsten is stepping down after leading the drugmaker’s research and development for the past 15 years, a period that includes Pfizer’s remarkable success ...

Also earlier this month, Pfizer said long-time Chief Scientific Officer Mikael Dolsten will leave the company after assisting in the search for his successor.

Pfizer Inc Mikael Dolsten; Independent Director; Pfizer Inc Aamir Malik; Chief US Commercial Officer, EVP; Pfizer Inc Alexandre De Germay; Executive Vice President, Chief International Commercial ...

Mikael Dolsten, Pfizer's outgoing chief scientific officer, said at a conference in March that the company hopes to launch its combination shot in 2025. It's unclear whether Friday's results ...